Evaluation on the efficacy and safety of Chinese herbal medication Xifeng Dingchan Pill in treating Parkinson's disease: study protocol of a multicenter, open-label, randomized active-controlled trial

医学 药丸 随机对照试验 打开标签 传统医学 协议(科学) 临床试验 帕金森病 替代医学 疾病 药理学 内科学 病理
作者
Jie Zhang,Yun-zhi Ma,Xiaoming Shen
出处
期刊:Journal of Integrative Medicine [Elsevier BV]
卷期号:11 (4): 285-290 被引量:19
标识
DOI:10.3736/jintegrmed2013035
摘要

Parkinson's disease (PD) is a complicated disease, commonly diagnosed among the elderly, which leads to degeneration of the central nervous system. It presently lacks an effective therapy for its complex pathogenesis. Adverse effects from Western drug-based medical intervention prevent long-term adherence to these therapies in many patients. Traditional Chinese medicine (TCM) has long been used to improve the treatment of PD by alleviating the toxic and adverse effects of Western drug-based intervention. Therefore, the aim of this study is to evaluate the efficacy and safety of Xifeng Dingchan Pill (XFDCP), a compound traditional Chinese herbal medicine, taken in conjunction with Western medicine in the treatment of PD patients at different stages in the progression of the disease. This is a multicenter, randomized controlled trial. In total, 320 patients with early- (n = 160) and middle-stage PD (n = 160) will be enrolled and divided evenly into control and trial groups. Of the 160 patients with early-stage PD, the trial group (n = 80) will be given XFDCP, and the control group (n = 80) will be given Madopar. Of the 160 patients with middle-stage PD, the trial group (n = 80) will be given XFDCP combined with Madopar and Piribedil, and the control group (n = 80) will be given Madopar and Piribedil. The Unified Parkinson's Disease Rating Scale scores, TCM symptoms scores, quality of life, change of Madopar's dosage and the toxic and adverse effects of Madopar will be observed during a 3-month treatment period and through a further 6-month follow-up period. It is hypothesized that XFDCP, combined with Madopar and Piribedil, will have beneficial effects on patients with PD. The results of this study will provide evidence for developing a comprehensive therapy regimen, which can delay the progress of the disease and improve the quality of life for PD patients in different stages. This trial has been registered in the Chinese Clinical Trial Registry with the identifer ChiCTR-TRC-12002150.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
猴子的应助被明亮白山采纳,获得10
刚刚
刚刚
领导范儿的应助被傻傻的灵寒采纳,获得10
1秒前
1秒前
1秒前
1秒前
HHW发布了新的文献求助10
2秒前
wanci的应助被牧百川采纳,获得10
2秒前
良行知发布了新的文献求助10
2秒前
2秒前
英姑的应助被jackson_WANG采纳,获得10
3秒前
tldsnhzrs完成签到,获得积分10
3秒前
小梅同学完成签到,获得积分10
4秒前
277发布了新的文献求助10
4秒前
5秒前
Jasper的应助被Ian采纳,获得150
5秒前
虚心楼房发布了新的文献求助10
5秒前
马秀玲发布了新的文献求助10
5秒前
5秒前
QIU完成签到 ,获得积分10
5秒前
6秒前
酷波er的应助被良行知采纳,获得10
9秒前
10秒前
酒辞发布了新的文献求助10
10秒前
10秒前
11秒前
喆减一发布了新的文献求助20
11秒前
情怀的应助被dianhuaxue采纳,获得10
12秒前
深情安青的应助被俭朴南风采纳,获得10
12秒前
13秒前
lili完成签到 ,获得积分10
13秒前
爆爆发布了新的文献求助10
13秒前
云海完成签到,获得积分10
14秒前
14秒前
Anna完成签到,获得积分10
15秒前
Licy完成签到,获得积分10
15秒前
15秒前
16秒前
干净的天蓉完成签到,获得积分20
16秒前
科研通AI6.4的应助被王萍有采纳,获得10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183298
求助须知:如何正确求助?哪些是违规求助? 9572606
关于积分的说明 21826444
捐赠科研通 7780272
什么是DOI,文献DOI怎么找? 3433993
关于科研通互助平台的介绍 2558136
邀请新用户注册赠送积分活动 2480259